LUCD earnings analysis
What we found in LUCD's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lucid Diagnostics delivered improving Q2 operating trends, with revenue up 26.7% year over year to $1.474 million, gross margin improving to approximately 2.0%, and diluted EPS improving sequentially to $(0.08) from $(0.17). However, operating expenses remained $14.275 million against $1.474 million of revenue, producing a $12.801 million operating loss, while six-month operating cash burn was $23.398 million. Management continues to disclose substantial doubt about going concern, remains dependent on reimbursement expansion and external financing, and faces a near-term Medicare-related debt waiver expiration on August 22, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 26.7% year over year
- Q2 2026 revenue increased to $1.474 million from $1.163 million in Q2 2025, a $0.311 million or 26.7% increase. Revenue was also up from $1.163 million in Q1 2026.
- Gross margin turned positive
- Gross margin improved to approximately 2.0% in Q2 2026, based on $1.474 million of revenue and $1.445 million of cost of revenue, versus negative 34.4% in Q2 2025 and negative 29.4% in Q1 2026.
- EPS improved sequentially
- Diluted EPS was $(0.08), unchanged from Q2 2025 but improved from $(0.17) in Q1 2026. Net loss attributable to common stockholders declined to $14.715 million from $7.888 million in the prior-year quarter only after reflecting $3.028 million of preferred-stock dividends in Q2 2026 versus $3.449 million in Q2 2025.
- First positive coverage policy secured
- The company secured its first positive laboratory benefit manager coverage policy in July 2026, under which EsoGuard is considered medically necessary for patients meeting American College of Gastroenterology screening criteria.
- Financing provided $22.3 million
- The April registered direct offering generated approximately $16.8 million of net proceeds from 18.0 million shares, while the ATM generated approximately $5.3 million of net proceeds from 4,161,747 shares during the six months ended June 30, 2026.
- Financing largely offset cash burn
- Six-month operating cash flow was negative $23.398 million and equipment purchases were $0.236 million, implying approximately $23.634 million of cash burn before financing. Financing activities provided $22.333 million, limiting the six-month cash decline to $1.301 million.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Going-concern uncertainty persists
- Management disclosed substantial doubt about the company's ability to continue as a going concern within one year. At June 30, 2026, cash was $33.404 million, six-month net loss attributable to common stockholders was $38.343 million, and operating cash flow used was $23.398 million.
- Debt and Medicare waiver risk
- The 2024 Convertible Notes had $21.975 million of face-value principal, a 12.0% stated interest rate, and a $23.500 million fair value at June 30, 2026. A waiver relating to the required positive Medicare decision only covered the period through August 22, 2026.
- Financing and dilution exposure
- The company remains dependent on equity and debt financing: it issued 18.0 million shares in the April offering and sold 4,161,747 ATM shares in the first half. In addition, 22,304,671 common shares remained in abeyance at June 30, 2026, creating potential future dilution.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
- Gross margin
- 2.0%
- Operating margin
- -868.5%
- Segment
- One reportable segment: consolidated EsoGuard/EsoCheck diagnostic testing operations. Q2 2026 revenue was $1.474 million versus $1.163 million in Q2 2025.
What they said about what is next.
No explicit numeric revenue or EPS guidance was provided. Management expects recurring losses and negative operating cash flow, and stated that operations will continue to be funded through debt and/or equity financings or refinancing existing debt.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Lucid Diagnostics reported a revenue increase to approximately $1.3 million for Q4 2026, compared to $0.8 million in the same quarter last year, reflecting a notable uptick in service demand. However, the company…
- 10-K · March 25, 2026
- Lucid Diagnostics (fiscal year ended 2025) showed modest commercial traction with revenue rising to $4,828,000 in 2025 from $3,976,000 in 2024 (an increase of $852,000, or ~21.4%), and sequential improvements in gross…
- 10-Q · August 12, 2025
- Lucid Diagnostics reported Q2 revenue of $1.163 million (up $0.187 million vs. $0.976 million in Q2 2024) and GAAP net loss per share improved to $(0.08) from $(0.23) a year ago. Gross margin materially improved to…
- 10-K · March 24, 2025
- Lucid Diagnostics presents a commercial-stage esophageal precancer screening test (EsoGuard) paired with a swallowable cell-collection device (EsoCheck) with strong analytical validation (e.g., ~97% analytical…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LUCD makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever